HormonesResearch PaperOpen Access

Erectile Dysfunction Hits 82% of Men With COPD, and Low Testosterone Isn't the Main Driver

In 44 men with moderate-to-severe COPD, 82% had erectile dysfunction and 70% low testosterone, yet ED tracked symptom burden, not testosterone.

Tuesday, November 17, 2026 0 views
Published in Int J Chron Obstruct Pulmon Dis
a pulmonologist discussing a questionnaire with a middle-aged male patient in a clinic exam room with a spirometer on the desk

Summary

Spanish researchers studied 44 men aged 40-75 with moderate-to-severe COPD to see how common erectile dysfunction (ED) and low testosterone are. ED affected 82% of the men, and 55% had severe ED. About 70% had low testosterone on a single morning blood test. Surprisingly, ED severity did not track with lung function or testosterone levels. Instead, it was linked to how much COPD affected daily life (the COPD Assessment Test), the number of other chronic illnesses, and depression and anxiety symptoms. A higher score on these routine measures independently predicted severe ED. The findings suggest that sexual health should be asked about routinely in COPD care, and that simple questionnaires already used in clinics can flag men at highest risk.

Detailed Summary

Chronic obstructive pulmonary disease (COPD) affects 10-13% of adults over 40 and is increasingly recognized as a systemic disease with cardiovascular, metabolic, muscular and psychological comorbidities. Erectile dysfunction (ED) and testosterone deficiency are common but rarely assessed in respiratory clinics, even though they signal vascular health and affect quality of life. This study asked how common both conditions are in COPD and what predicts severe ED.

This cross-sectional, multicenter study enrolled men aged 40-75 with stable moderate-to-severe COPD from six Spanish hospitals. Of 55 enrolled, 44 completed the International Index of Erectile Function (IIEF) and formed the primary analysis set (mean age 65.1, FEV1 50.4% predicted, 56 pack-years). Men already treated for ED or hypogonadism, or on home oxygen, were excluded. Testosterone was measured once, fasting, in the morning, and symptoms were scored with the Aging Males' Symptoms Scale (AMSS).

ED was present in 81.8% of men, and 54.5% had severe ED (erectile function domain score 10 or below). Mean total testosterone was 208.3 ng/dL, and 70.5% fell below 300 ng/dL. Among 33 men with AMSS data, 75.8% had symptoms compatible with androgen deficiency, and 54.5% had moderate-to-severe symptoms. ED affected every IIEF domain, including desire, orgasm and satisfaction. Agreement between low testosterone and symptoms was poor (kappa -0.128).

Men with severe ED were older (67.3 vs 62.6 years, p=0.049) and had worse dyspnea (mMRC 2 or higher: 70.8% vs 25%, p=0.004), higher CAT scores (22.2 vs 9.6, p<0.001), higher BODEx (3.94 vs 1.1, p=0.001) and higher Charlson comorbidity index (2.3 vs 1.3, p=0.012). They also had higher HbA1c (6.01% vs 5.7%, p=0.017), lower total cholesterol, more depressive symptoms (HADS-D 6.65 vs 3.8, p=0.021), worse urinary symptoms, and higher LH and FSH. FEV1, DLCO and testosterone did not differ.

In multivariable logistic regression, higher CAT, comorbidity burden and psychological distress independently predicted severe ED. The authors built an exploratory risk-stratification approach using cut-offs of CAT above 10, Charlson index above 3 and HADS above 15, with bootstrap validation. Practically, a routine, free questionnaire like the CAT could help clinicians identify who to ask about sexual health, and the results argue for integrating sexual health assessment into COPD care rather than focusing on spirometry alone.

The study has important caveats. The sample is small (44), and 11 enrolled men lacked IIEF data and were older with better lung function, raising selection bias risk. Testosterone was measured once, so it reflects biochemical deficiency rather than a confirmed hypogonadism diagnosis. Some questionnaires were incomplete, the cross-sectional design prevents causal inference, and the risk model was exploratory with wide uncertainty and no external validation.

Key Findings

  • ED was present in 81.8% of 44 men with moderate-to-severe COPD, and 54.5% had severe ED
  • Biochemical testosterone deficiency (<300 ng/dL, single morning sample) occurred in 70.5%; mean total testosterone 208.3 ng/dL
  • Severe ED was linked to higher CAT scores (22.2 vs 9.6, p<0.001) and mMRC dyspnea of 2 or higher (70.8% vs 25%, p=0.004)
  • Severe ED was linked to higher Charlson comorbidity index (2.3 vs 1.3, p=0.012) and higher HbA1c (6.01% vs 5.7%, p=0.017)
  • Depressive symptoms were higher in severe ED (HADS-D 6.65 vs 3.8, p=0.021); FEV1 and testosterone did not differ between groups
  • Agreement between low testosterone and androgen-deficiency symptoms was poor (kappa -0.128, p=0.443)
  • Higher CAT, comorbidity burden and psychological distress independently predicted severe ED

Methodology

Observational, cross-sectional, multicenter study across six Spanish respiratory clinics, with 44 men with stable moderate-to-severe COPD in the primary analysis (55 enrolled). ED was graded by the IIEF, androgen symptoms by AMSS, and testosterone from one fasting morning sample. Groups were compared with Mann-Whitney, chi-square or Fisher tests, and Spearman correlations. Two backward stepwise logistic regression models were built with multiple imputation, Hosmer-Lemeshow calibration, ROC curves and 1000-iteration bootstrap.

Study Limitations

The sample was small and 11 enrolled men lacked IIEF data and differed from included participants (older, better lung function), creating possible selection bias. Testosterone was measured only once, so it cannot confirm hypogonadism, and some questionnaires were incomplete. The cross-sectional design precludes causality, and the risk-stratification model is exploratory, with cut-offs partly data-derived and no external validation.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: